Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/1843/60618
Tipo: | Artigo de Periódico |
Título: | COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma |
Autor(es): | Marco Aurelio Petroni Montezuma Felipe Paiva Fonseca Bernar Monteiro Benites Ciro Dantas Soares Gleyson Kleber do Amaral Silva Oslei Paes de Almeida Fernando Augusto Soares Rosana Lima Pagano Eduardo Rodrigues Fregnani |
Resumo: | Ameloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue microarray were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients' medical records and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm2. COX-2 was significantly associated with recurrences (p < 0.001) and BRAF-V600E expression (p < 0.001), whereas lower MVD was associated with the use of conservative therapy (p = 0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p < 0.001 and p = 0.012, respectively), but not with a higher MVD (p = 0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS. |
Assunto: | Ameloblastoma Antigens, CD34 Odontogenic tumors Cyclooxygenase 2 Microvascular density Survival rate |
Idioma: | eng |
País: | Brasil |
Editor: | Universidade Federal de Minas Gerais |
Sigla da Instituição: | UFMG |
Departamento: | FAO - DEPARTAMENTO DE CLÍNICA |
Tipo de Acesso: | Acesso Restrito |
Identificador DOI: | https://doi.org/10.1016/j.prp.2018.03.014 |
URI: | http://hdl.handle.net/1843/60618 |
Data do documento: | Jun-2018 |
metadata.dc.url.externa: | https://www.sciencedirect.com/science/article/pii/S034403381830092X?via%3Dihub |
metadata.dc.relation.ispartof: | Pathology - Research and Practice |
Aparece nas coleções: | Artigo de Periódico |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.